Subtle Medical, an AI-based medical imaging company, has received Phase 2 funding from an NIH Small Business Innovation Research (SBIR) grant to expand its SubtleSYNTH technology into brain imaging.
The company received FDA approved To generate synthetic short tau inversion recovery (STIR) images (SynthSTIRs) from previously acquired T1- and T2-weighted contrasts in spine images.
According to the company, this approval represents a major advancement in MRI technology, enabling SynthSTIR to achieve zero image acquisition time while maintaining clinical quality similar to conventional STIR images.
SubtleSYNTH is the latest addition to the company’s AI-based product family, which also includes SubtleMR and SubtlePET software.
SubtleSYNTH aims to improve the efficiency and accuracy of MRI procedures, benefiting both patients and the imaging companies they serve by eliminating backlogs, long wait times, and scheduling issues, the company said in a statement.
“We are very excited to have received this second round of funding to scale our SubtleSYNTH technology,” Ajit Shankaranarayanan, chief product officer at Subtle Medical, said in a statement.
“This grant not only validates the scientific merit of our approach, but also empowers us to push the boundaries of what is possible in medical imaging. With FDA clearance for spine imaging and support from NIH, we are well positioned to bring this innovative technology to brain imaging, further improving the speed, quality, and safety of MRI examinations.”
The bigger trend
July 24th, subtle medical The company raised nearly $10 million in its Series B+ round, bringing its Series B funding to over $30 million and its total funding to over $50 million.
The funds were used to accelerate U.S. and global sales initiatives and advance the launch of new AI-based products.
SubtleSYNTH complements the company’s previous FDA approved SubtleMR software accelerates image acquisition for MRI procedures by up to 60% across all vendors.
The HIMSS Healthcare Cybersecurity Forum will be held in Washington, DC from October 31 to November 1.
